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The tripartite efflux pump assembly AcrAB-TolC is the major multidrug resistance
transporter in E. coli. The inner membrane transporter AcrB is a homotrimer, energized
by the proton movement down the transmembrane electrochemical gradient. The
asymmetric crystal structures of AcrB with three monomers in distinct conformational
states [access (A), binding (B) and extrusion (E)] support a functional rotating mechanism,
in which each monomer of AcrB cycles among the three states in a concerted
way. However, the relationship between the conformational changes during functional
rotation and drug translocation has not been totally understood. Here, we explored the
conformational changes of the AcrB homotrimer during the ABE to BEA transition in
different substrate-binding states using targeted MD simulations. It was found that the
dissociation of substrate from the distal binding pocket of B monomer is closely related to
the concerted conformational changes in the translocation pathway, especially the side
chain reorientation of Phe628 and Tyr327. A second substrate binding at the proximal
binding pocket of A monomer evidently accelerates the conformational transitions as well
as substrate dissociation in B monomer. The acceleration effect of the multi-substrate
binding mode provides a molecular explanation for the positive cooperativity observed
in the kinetic studies of substrate efflux and deepens our understanding of the functional
rotating mechanism of AcrB.
Keywords: AcrB, MD simulation, substrate binding, allosteric effect, drug extrusion, positive cooperativity
Introduction
In Gram-negative bacteria, resistance-nodulation-division (RND) superfamily proteins play a
major role in the eﬄux of a wide range of antibiotics and toxic compounds out of cell. RND
superfamily, together with other classes of multidrug eﬄux pumps, constitute one of the major
mechanisms of multidrug resistance (MDR) in bacteria, which represents a serious impediment
to improved healthcare (Higgins, 2007). RND transporter is embedded in the inner membrane
and works as a drug-proton antiporter. Fueled by proton diffusion down the transmembrane (TM)
electrochemical gradient, it collects substrates from the periplasm or the inner leaflet of inner mem-
brane and extrudes them to the lumen of outer membrane component (Nikaido, 1996). The RND
transporter AcrB in Escherichia coli has been extensively studied as a prototype of the family, which
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exports a number of dyes, detergents, chloramphenicol, tetracy-
clines, macrolides, β-lactams, fluoroquinolones, and organic sol-
vents. It functions in the form of AcrAB-TolC tripartite complex
(Zgurskaya and Nikaido, 1999b; Tikhonova and Zgurskaya, 2004;
Collu et al., 2012; Du et al., 2014) by working collaboratively with
the periplasmic adaptor protein AcrA (Zgurskaya and Nikaido,
1999a; Mikolosko et al., 2006) and the outer membrane protein
TolC (Koronakis et al., 2000). As the core of the complex, AcrB
is responsible for substrate recognition and energy supplement
(Elkins and Nikaido, 2002).
Crystallographic studies have revealed the structure of AcrB as
a homotrimer (Murakami et al., 2002, 2006; Seeger et al., 2006).
Each monomer is composed of a TM domain, a porter domain
and a TolC-docking domain (Figure 1A). The TM domain con-
tains 12 TM helices and encompasses a putative proton relay
pathway lined by Asp407 and Asp408 on TM4 helix, Lys940 on
TM10 helix and Thr978 and Arg971 on TM11 helix, which har-
vests proton motive force from the transmembrane electrochem-
ical gradient (Murakami et al., 2006; Seeger et al., 2006, 2009; Su
et al., 2006; Takatsuka and Nikaido, 2006). The porter domain
and the TolC docking domain are folded by two periplasmic
loops of the TM domain, one between TM1 and TM2 helices
and the other between TM7 and TM8 helices. The porter domain
could be further divided into four subdomains PN1, PN2, PC1,
and PC2 (Figure 1B), the inter-domain space between which
forms the pathway for substrate translocation (Sennhauser et al.,
2007; Husain and Nikaido, 2010; Nakashima et al., 2011; Yao
et al., 2013). Despite of the diversity of entrances (Husain and
Nikaido, 2010; Nakashima et al., 2011; Yao et al., 2013), sub-
strates are found to constantly pass through the cleft between
PC1 and PC2, the “switch-loop” (also called Phe-617 loop, G-
loop), the cavity enclosed by PC1, PN1, and PN2, and the exit
constricted by Gln124 (on PN1 subdomain) and Tyr758 (on
the TolC-docking domain) (Figure 1B) during the transloca-
tion process, and finally enter the central funnel enclosed by the
TolC-docking domains. Two binding pockets have been identi-
fied along the translocation pathway inside the porter domain.
The pocket more distal from the entrances, i.e., the distal binding
pocket (DBP), lies between PC1 and PN2 and is rich in aromatic
residues including Phe610, Phe615, Phe617, and Phe628 on PC1
and Phe136 and Phe178 on PN2 (Figure 1B) (Murakami et al.,
2006; Nakashima et al., 2011; Eicher et al., 2012). The proxi-
mal binding pocket (PBP, also called access pocket) between PC1
and PC2 is more hydrophilic (Figure 1B), capturing substrates
through a combination of hydrogen bond, hydrophobic and pi-
pi stacking interactions (Nakashima et al., 2011; Eicher et al.,
2012).
AcrB is highly dynamic and its conformational changes are
essential for its transport activity (Takatsuka and Nikaido, 2007,
2009; Seeger et al., 2008). Three major conformational states of
monomers have been identified in the asymmetric crystal struc-
tures (Murakami et al., 2006; Seeger et al., 2006; Sennhauser
et al., 2007; Nakashima et al., 2011; Eicher et al., 2012). The
access (A, also called loose, L) and binding (B, also called tight,
T) states both have an opened PC1/PC2 cleft and an occluded
exit, but differs in the binding pockets. The DBP in B state is
intact and capable of accommodating substrates, whereas in A
state, the DBP partially collapses and the PBP is found capable of
substrate binding instead (Nakashima et al., 2011; Eicher et al.,
2012). The extrusion (E, also called open, O) state adopts a
closed PC1/PC2 cleft and an opened exit for substrate extru-
sion. Edified by the asymmetric crystal structures, eachmonomer
of AcrB trimer is believed to undergo a succession of transi-
tions among the three states during transportation, cycling from
A to B to E and back to A state, i.e., the functional rotating
mechanism (Murakami et al., 2006; Seeger et al., 2006; Pos,
2009). The mechanism also predicts that the transition of each
monomer is dependent on the conformations of its neighbors.
When A monomer (originally staying in A state) evolves to B
state, B and E monomers would respectively switch into E and A
states simultaneously, accomplishing one ABE→BEA transition
step.
The functional rotating mechanism implicates highly cooper-
ative conformational changes among the three monomers. Sub-
sequent kinetic studies indeed revealed positive cooperativity in
substrate eﬄux (Nagano and Nikaido, 2009; Lim and Nikaido,
2010). However, the underlying detailed picture of the functional
rotating and the cooperativity in substrate eﬄux remain elusive,
especially the relationship between the conformational changes
in AcrB and the kinetic behavior of substrate eﬄux. Molecular
dynamics (MD) simulation is a powerful tool in providing high
spatiotemporal resolution details for conformational changes of
proteins. MD simulations have been used to reveal the dynam-
ics of RND transporters (Fischer and Kandt, 2013; Yamane et al.,
2013), the movement of substrate (Fischer and Kandt, 2011; Feng
et al., 2012) and the interaction network between the trans-
porter and substrate (Vargiu and Nikaido, 2012; Kinana et al.,
2013). Due to the sampling efficiency problem of the conven-
tional MD simulation, some enhanced sampling protocols, such
as targeted MD (Ma and Karplus, 1997; Kong et al., 2002; van
der Vaart et al., 2004; Compoint et al., 2005; Cheng et al., 2006;
Weng et al., 2010, 2012), were also implemented to extract details
of the conformational transition in one functional rotating step
(Schulz et al., 2010, 2011; Vargiu et al., 2011). In this work, we
performed targeted MD simulations to investigate the confor-
mational transition with different number of binding substrates.
Binding of one or two molecules of doxorubicin show similar
concerted conformational changes in the translocation pathway
and the dissociation of substrate from the DBP. A close correla-
tion was observed between side chain reorientations of Phe628
and Tyr327 and substrate dissociation in both systems. Bind-
ing of a second substrate evidently facilitates the conformational
changes in the translocation pathway as well as the dissociation of
the DBP-bound substrate, explaining the positive cooperativity in
substrate transportation.
Materials and Methods
System Setup
The crystal structure of AcrB (PDBID: 2GIF) was used as the
starting structure of all simulations. In the crystal structure,
residues 1034–1049 are missing in chain A and C, and residues
1046–1049 are missing in chain B. To keep the 3-fold symme-
try of the protein, we truncated the residues 1034–1045 in chain
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FIGURE 1 | Conformational changes of the translocation pathway in
the dox system. (A) Simulation system of AcrB trimer buried in POPE
bilayer and solvated with water molecules. A, B, and E monomers of AcrB in
cartoon representation are colored in cyan, green and blue, respectively.
Doxorubicin bound in the DBP of B monomer is shown in the VDW
representation (yellow). Lipid molecules are colored in red with the charged
head groups shown as balls and the hydrophobic tails as sticks. Some lipid
molecules are removed for clarity. (B) A schematic view of the substrate
translocation pathway in B monomer (gray lines). Subdomains PC1, PC2,
PN1, and PN2 are colored in blue, cyan, dark green, and green, respectively.
The residues lining the DBP is represented by the licorice mode and colored
by atom type (C: salmon, O: red, N: blue). Residues Qln124 and Tyr758 that
form the exit gate are also indicated. (C) Variation of the Cα
root-mean-square deviation (RMSD) of the porter domain in B monomer
relative to the target structure. (D) Variations of the distance between the
mass centers of PC1 and PC2 subdomains. (E) Variations of the radius of
gyration of DBP in B monomer. (F) Variations of the Gln124-Tyr758
inter-residue distance at the exit gate. The coordinate of each residue is
represented by its Cα atom. For simplicity, we use the targeted MD simulation
time to describe the conformational transition events in the text, but it is
worth noting that the simulation time only denotes the relative progress of the
targeted MD trajectories and is not necessarily proportional to actual time.
B. Since no substrate was cocrystallized in this structure, one
doxorubicin was docked into the DBP of B monomer according
to the AcrB-doxorubicin complex structure (PDBID: 2DR6). In
the simulations with two substrates, the second doxorubicin was
docked into the PBP of A monomer by using Autodock (Morris
et al., 2009). Default parameters were used for the docking pro-
cedure and the center structure of the largest cluster was selected
for the simulations.
The AcrB-doxorubicin complex was then buried into a pre-
equilibrated palmitoyloleoylphosphatidylethanolamine (POPE)
bilayer consisting of 512 lipid molecules following the “shrink-
ing” method (Kandt et al., 2007). Additional 10 lipid molecules (5
lipids in the outer leaflet and 5 in the inner leaflet) were manually
placed in the central cavity enclosed by the three TM domains.
The number of lipids was estimated by the area of the cavity
calculated by Hole (Smart et al., 1996) divided by the area per
lipid for POPE (59 Å2) (Rappolt et al., 2003). The protein-lipids
complex were solvated with a rectangular box of water and neu-
tralized by 42 Na+ ions. The box size is 140 × 140 × 160 Å3 to
keep any atom of protein at least 10 Å away from the edge of
the box. The simulation system contains 320,557 atoms in total
(Figure 1A).
MD Simulations
All simulations were carried out with the parallel MD pack-
age NAMD 2.7 (Phillips et al., 2005) with CHARMM27 force
field (Feller et al., 1997; MacKerell et al., 1998, 2004). TIP3P
model (Jorgensen et al., 1983) was used for water molecules. The
CGenFF force field parameters of doxorubicin were derived by
using the ParamChem tool (Vanommeslaeghe et al., 2010, 2012;
Vanommeslaeghe and MacKerell, 2012). All titratable residues
were kept in their default protonation states except Asp407
and Asp408. For these two residues, two different protona-
tion schemes were used. In the first scheme, the protonation
states were set according to the asymmetric structure of AcrB
(Murakami et al., 2006), i.e., Asp407 and Asp408 were depro-
tonated in the A and B monomers, and protonated in the E
monomer. In the second scheme, Asp407 and Asp408 were pro-
tonated in the B monomer and deprotonated in the A and E
monomers. The system was maintained at 1.01325 bar by using
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the Nosè-Hoover Langevin piston method (Martyna et al., 1994;
Feller et al., 1995) and at 300 K by Langevin dynamics with a
damping coefficient of 1.0 ps−1. Periodic boundary conditions
were employed, and the electrostatic interactions were evaluated
using the particle-mesh Ewald (PME) method (Darden et al.,
1993) with a cutoff of 12 Å and a grid spacing of 1 Å. The van
der Waals interactions were switched at 10 Å and truncated at 12
Å. All bonds involving hydrogen atoms were constrained by the
SETTLE algorithm (Miyamoto and Kollman, 1992). A time step
of 2 fs was used for the conventional MD simulations, and 1 fs
was used for the targeted MD simulations.
The whole system was equilibrated for 2 ns with the protein
restrained by harmonic forces (the force constant was set to 1000
kcal/mol/Å2), followed by a 4 ns run without any restraint. AcrB
was stable in the 4 nsNPT runwith its Cα root-mean-square devi-
ation (RMSD) relative to the initial crystal structure fluctuating
around 2.2 Å in the last 2 ns. The final structure of the unbi-
ased MD run was used as the initial structure of the targeted MD
simulations. The target structure was obtained by setting each
monomer to the state of the next functional rotating step, i.e.,
ABE→BEA.
Targeted MD method propels a known initial structure to a
known target structure by using an external potential (Schlitter
et al., 1993). The potential decreases the RMSD of the system rel-
ative to the target structure toward a preset value at each time
step. The potential can be described as:
UTMD =
1
2
k
N
[
RMSD(t)− RMSD ∗ (t)
]2
where RMSD(t) is the instantaneous best-fit RMSD of the cur-
rent coordinates to the target coordinates, RMSD∗(t) is the preset
RMSD value for the current time step, k is the force constant
and N is the number of targeted atoms. The external forces were
casted on all heavy atoms of AcrB. A tclForce script was used to
perform mass-weighted targeted MD simulations. To assess the
influence of parameters on the results, we performed a series of
simulations using different force constants (k/N = 1, 2, and 3
kcal/mol/Å2) and different simulation times (500 ps and 1 ns)
(Table S1, Supplemental Data).
Data Analyses
The radius of gyration (Rg) of the DBP is defined by all the atoms
in the residues 628, 610, 136, 178, 615, 617, 277, 626, 620, 176,
and 612 which lies in the vicinity of DBP:
Rg =
(
n∑
i= 1
ω (i) (r (i)− rmc)
2
)
/
(
n∑
i= 1
ω (i)
)
where r(i) is the position of the ith atom, ω(i) is the mass weight
and rmc is the weighted center of the selected atoms. The distance
between Gln124 & Tyr758 is defined as the distance between
the Cα atoms of the two residues. All data analysis and molec-
ular structure visualization were conducted by VMD (Humphrey
et al., 1996).
Results
We employed targeted MD simulations to acquire an atomistic
view of the conformation changes of AcrB in one functional
rotating step. The conformational changes were studied with one
doxorubicin bound in the DBP of B monomer (denoted as dox
hereafter), or with two doxorubicins bound in the DBP of B
monomer and in the PBP of Amonomer, respectively (denoted as
2dox hereafter). Three parallel trajectories started with different
initial velocities were produced for each system. The results were
found to be insensitive to the selection of force constants or time
lengths (Table S1, Supplemental Data, see below for details). In
the following, we will first introduce the collective and local con-
formational changes in the translocation pathway and the asso-
ciation of these changes with doxorubicin movement. Then we
focus on the effect of the presence of the second doxorubicin by
comparing the trajectories of the dox and 2dox systems. For sim-
plicity, we use the targeted MD simulation time to describe the
conformational transition events in the text, but it is worth not-
ing that the simulation time only denotes the relative progress of
the targeted MD trajectories and is not necessarily proportional
to actual time.
Concerted Conformational Changes in the
Translocation Pathway of B Monomer
At the beginning of the simulation, large-scale conformational
changes were observed in the porter domain of the B monomer
(Figure 1B). In all three trajectories of the dox system, the Cα
RMSDs of the porter domain decreased linearly relative to the
targeted structure in the first 330 ps, after which the RMSD
profiles fluctuated around 1.7 Å till the end of the simulations
(Figure 1C). The variations of the porter domain are largely
resulted from the relative motions between the subdomains. The
motions reduced the distance between the mass centers of PC1
and PC2 subdomains from 26.6 to 22.8 Å in 330 ps (Figure 1D),
closing the PC1–PC2 cleft and occluding the translocation path-
way toward the entrance (Figure 1B). On the other hand, the
DBP shrunk from ∼100 ps, with the Rg decreasing till the end
of the simulations (Figure 1E). The decline of Rg indicates con-
traction of the middle part of the translocation pathway which
would contribute to the dissociation of substrate (see below).
During this period, the distance between residues Gln124 and
Tyr758, which constrict the exit of drug extrusion (Yao et al.,
2013) (Figure 1B) increased from 8.7 to 13.1 Å in about 180 ps
(Figure 1F), resulting in the opening of the exit. It is worth not-
ing that the timing of these conformational changes obviously
overlap with each other, with the exit gate opening at 155–340 ps
(Figure 1F), the PC1/PC2 cleft closing at 50–330 ps (Figure 1D)
and the DBP shrinking at 75–500 ps (Figure 1E), indicating con-
certed conformational motions of the translocation pathway in
the first 330 ps of the simulations.
Dissociation of Doxorubicin from the DBP
As the concerted transmutation of the translocation pathway
started in the first 155 ps, the substrate kept stably bound inside
the DBP through hydrophobic and pi-pi interactions with the
protein (Figure S1, Supplemental Data). The binding mode in
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FIGURE 2 | Dissociation of doxorubicin from the DBP in the dox
system. (A) Close view of doxorubicin (yellow) bound in DBP in the initial
structure. Residues lining the DBP are colored by atom type (C: salmon, O:
red, N: blue), except Phe628, Val571, and Tyr327, which are highlighted by
green and purple. (B) Variations of the distance between doxorubicin and the
DBP with simulation time. (C) Snapshot of doxorubicin in DBP at 230 ps in
one of the trajectories when Phe628 reoriented and pointed toward the
substrate. (D) Variations of χ1 angle of Phe628 along the simulation
trajectories. (E) Close view of doxorubicin and the residues lining DBP at the
end of the simulation when Tyr327 inserted in between Phe628 and Val571.
(F) Variations of the distance between the mass center of Tyr327 side chain
and the Cα atom of Phe628.
the simulations is slightly different from the two known bind-
ing modes presented in crystal structures (Murakami et al., 2006;
Eicher et al., 2012). The position of the amino-sugar moiety was
almost invariant, whereas the aglyconemoiety showed a new pos-
ture by extending directly toward Phe628 rather than pointing
toward Phe610 (Eicher et al., 2012) or Phe617 (Murakami et al.,
2006) in the crystal structures (Figure S1, Supplemental Data).
The diversity of binding mode could be attributed to the differ-
ences in the local configuration of the DBP in different crystal
structures (see Methods). Similar structural dependence of bind-
ing mode was also reported for chloramphenicol in the DBP of
AcrB (Vargiu and Nikaido, 2012).
The stable interactions between doxorubicin and DBP were
disrupted at 225–300 ps as doxorubicin detached from the bind-
ing site. The dissociation of doxorubicin was monitored by the
distance between the mass center of doxorubicin and the Cα
atom of Phe628 which lies at the bottom of the DBP (Figure 2A).
Two of the trajectories exhibit very similar profiles of substrate
motions. The doxorubicin initially stayed in the DBP with the
distance fluctuating around 12.5 Å, and detached from the bind-
ing site after 300 ps as the distance increased (Table1, Figure 2B,
pink and red lines). In another trajectory, more evident fluctua-
tions were observed before dissociation, such as the peak at 225 ps
on the profile (Figure 2B, brown line). After 275 ps, doxorubicin
became fully dissociated from the DBP. At the end of the simula-
tions, a displacement of 5–7 Å toward the exit could be observed
and the dissociation is irreversible, as verified by the extended
2-ns simulations with all restraining forces removed (Figure S2,
Supplemental Data). Similar extrusion process was also observed
by Vargiu et al. using targeted MD simulations (Vargiu et al.,
2011).
Correlation between the Conformational
Changes in the DBP and Doxorubicin
Dissociation
Further inspection of the trajectories show that the dissocia-
tion process of doxorubicin is closely related to the conforma-
tional changes of the DBP, especially the side chain orienta-
tion of Phe628. The benzyl group of Phe628 originally pointed
toward the TM domain at the beginning of the simulations,
characterized by the χ1 angle of about −160◦ (Figure 2A), and
then it switched to a new orientation with the χ1 angle at
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TABLE 1 | Conformational changes associated with the dissociation of
doxorubicin.
Systema Trajectory Time of
doxorubicin
dissociation
(ps)b
Time of Phe628
side chain
reorientation
(ps)c
Time of Tyr327
side chain
insertion (ps)d
dox 1 225, 275 225 235–500
2 300 300 300–395
3 300 300 300–470
2dox 1 200 200 200–400
2 225 225 225–370
3 190 190 190–420
adox denotes the simulation system with only one doxorubicin bound in DBP of B
monomer, 2dox denotes the simulation system with a second doxorubicin bound in PBP
of A monomer.
bTime when doxorubicin detached from the binding pocket. Temporary dissociation leads
to more than one dissociation time.
cTime when Phe628 reoriented its side chain and pointed toward the substrate.
dTime period of the decreasing of the distance between Tyr327 side chain and
Phe628 Cα.
about −60◦ (Figures 2A,C,D). The reorientation of Phe628 side
chain occurred at 300 ps in two of the trajectories (Figure 2D,
pink and red lines) and at 225 ps in the other (Figure 2D,
brown line), well consistent with the departure time of doxoru-
bicin (Table 1). The close correlation between the two events
can be rationalized by the steric hindrance between the bulky
side chain of Phe628 and the doxorubicin at binding site
(Figure 2C), which pushes the substrate from the binding pocket.
The importance of Phe628 for substrate dissociation was previ-
ously reported by biochemical studies, in which substitution of
the bulky side chain reduced the resistance to doxorubicin and
other substrates (Husain and Nikaido, 2010; Nakashima et al.,
2011).
After the reorientation of Phe628, local conformational rear-
rangement was observed. The space originally occupied by the
benzyl group of Phe628 and the isopropyl group of Val571
(Figures 2A,C) was subsequently filled by the phenol group of
Tyr327, which is several residues preceding TM2 helix of the
TMdomain (Figure 2E). Interestingly, the rearrangement started
almost simultaneously with the reorientation of the Phe628 side
chain (Figure 2F, Table 1). This implies a functional role of
Tyr327 in stabilizing the reorientated conformation of Phe628.
To examine possible influence of TM domain protonation
state on substrate dissociation, we produced targeted MD trajec-
tories for AcrB with different protonation state (Table S1, Sup-
plemental Data). It turns out that these trajectories demonstrated
very similar features such as substrate dissociation, side chain
reorientation of Phe628 and Tyr327 (Figure S3, Table S1, Sup-
plemental Data), indicating that the current simulation proto-
col is insensitive to the changes in protonation state. Different
simulation time range (500 ps or 1 ns) and different force con-
stant (k/N = 1, 2, or, 3 kcal/mol/Å2) were also tested. These
factors do not disturb the correlation between conformational
changes in the DBP and substrate dissociation, either (Table S1,
Supplemental Data).
Binding of the Second Doxorubicin Accelerates
the Conformational Changes in the Translocation
Pathway
To study the effect of multi-substrate binding on the confor-
mational transition, a second doxorubicin was docked into the
PBP of A monomer (see Methods) to build the 2dox system
(Figure 3A). The position of the docked substrate closely resem-
bles the binding mode of PC1-proximal doxorubicin (Figure
S4, Supplemental Data) observed in the AcrB-doxorubicin com-
plex structure (Eicher et al., 2012). The presence of the second
doxorubicin affects the conformational changes in the translo-
cation pathway in several aspects. First, the closing motion of
the PC1/PC2 cleft was antedated, illustrated by the ∼70 ps ear-
lier decreasing period of the inter-domain distance in the 2dox
system than that in the dox system (Figure 3B). Secondly, the
conformational changes in the DBP were moved ahead as the Rg
decreased to 7.8 Å at about 200 ps in the 2dox system, instead
of at 300 ps in the dox system (Figure 3C). Finally, the open-
ing motion of the exit was accelerated as the distance between
Gln124 and Tyr758 exceeded 13 Å at 220 ps, rather than at 300 ps
in the dox system (Figure 3D). It is worth noting that the dox and
2dox systems share very similar initial and final structures at the
PC1/PC2 cleft, the DBP and the exit gate (Figures 3B–D), so that
the external forces casted on these regions are generally equiv-
alent in both systems (see Methods). The systematic antedate
of these events indicates that the conformational changes in the
translocation pathway are evidently accelerated by the binding of
the second doxorubicin at A monomer.
Binding of the Second Doxorubicin Facilitates
the Dissociation of Doxorubicin
Along with the antedated conformational changes in the translo-
cation pathway, substrate dissociation in the 2dox system was
also earlier than that in the dox system. In the three trajecto-
ries, irreversible dissociation occurred at 200, 230, and 190 ps,
respectively (Figure 4A, Figure S5, Supplemental Data), about 70
ps earlier than that of the dox system on average. Along with sub-
strate dissociation, the change of Phe628 χ1 angle from −160 to
−60◦ and the insertion of Tyr327 in between Phe628 and Val571
were also moved ahead to about 200 ps (Figures 4B,C). Similar
with the dox system, there is also a close correlation between
substrate dissociation and side chain reorientation of Phe628
and Tyr327 (Table 1) and the trend is kept with varied simula-
tion time range or force constant (Table S1, Supplemental Data),
indicating that the 2dox system shares the same mechanism of
doxorubicin dissociation in B monomer with the dox system.
Conformational Changes in AcrB Does Not
Promote the Transportation of the Second
Doxorubicin
The movement of doxorubicin in the PBP of A monomer dur-
ing the functional rotation was also examined (Figure 3A). In
contrast to the displacement toward the exit observed for the
DBP-bound doxorubicin in B monomer, the PBP-bound dox-
orubicin in A monomer moved in an opposite direction, further
away from the DBP by about 2 Å at the end of the simulations
(Figure 5A). The slight retrogression of the substrate could be
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FIGURE 3 | The second substrate binding at A monomer accelerates
the conformational changes of B monomer. (A) Top view of the porter
domains with two doxorubicins (yellow and orange) bound in the initial
structure of the 2dox system. The distance between doxorubicin and DBP in
A monomer is indicated as DA
DOX−DBP
. (B) Comparison of the variations of
the distance between the mass centers of PC1 and PC2 subdomains of B
monomer in dox and 2dox systems. (C) Comparison of the variations of Rg
of the DBP of B monomer in dox and 2dox systems. (D) Comparison of the
variations of the Gln124-Tyr758 inter-residue distance at the exit region of B
monomer in dox and 2dox systems.
FIGURE 4 | The second substrate binding at monomer A
accelerates the dissociation of doxorubicin from the DBP in
monomer B. (A) Comparison of the variations of the distance between
doxorubicin and the DBP of monomer B in dox and 2dox systems. (B)
Comparison of the variations of χ1 angle of Phe628 in dox and 2dox
systems. (C) Comparison of the variations of the distance between the
mass center of Tyr327 side chain and the Cα atom of Phe628 in dox
and 2dox systems.
attributed to the inter-domain motion between PC1 and PC2
subdomains. The PC1/PC2 cleft opened by about 1.5 Å when
A monomer evolved toward the B state following the func-
tional rotating mechanism (Figure 5B). The opening motion
may weaken the interactions between AcrB and doxorubicin, and
leads to the movement of substrate toward the entrance.
Discussion
The functional rotating mechanism based on the asymmetric
structure of AcrB assumes that each monomer cycles among the
three conformational states (A, B, and E) concertedly, facilitat-
ing the unidirectional translocation of the substrate toward the
outer membrane protein TolC. In this work, we simulated one
functional rotating step of AcrB (ABE→BEA) in the context of
one or two bound substrates using targeted MD simulations, and
provided an atomic spatiotemporal view of the conformational
changes and substrate movement.
The targeted MD trajectories demonstrated that the simula-
tion started with conformational changes in the translocation
pathway, involving a set of concerted motions such as the clos-
ing of the PC1/PC2 cleft (Figure 1D), the shrinking of the DBP
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FIGURE 5 | Conformational transition of A→B does not facilitate substrate translocation from PBP to DBP. (A) Variations of DA
DOX−DBP
along the
simulation trajectories. (B) Variations of the distance between the mass centers of PC1 and PC2 subdomains in A monomer.
(Figure 1E), and the opening of the exit gate (Figure 1F). In
the following 200 ps, however, doxorubicin in DBP did not
show evident motions until the dissociation from DBP occurred
at 225–300 ps. Therefore, the conformational changes in the
translocation pathway are the prerequisite and the driving force
for substrate dissociation. Specifically, it has been identified that
the side chain reorientation of Phe628 is mainly responsible
for substrate dissociation (Figure 2). The importance of Phe628
for substrate transportation is supported by previous biochem-
ical experiments, in which removal of the bulky side chain of
Phe628 evidently reduced the resistance to doxorubicin and
other substrates of AcrB (Husain and Nikaido, 2010; Nakashima
et al., 2011). Similar protein-driven substrate movement was also
observed by A. Vargiu et al. using the same method (Schulz et al.,
2010; Vargiu et al., 2011) though the atomistic details of protein-
substrate interaction are slightly different. Due to the limited sim-
ulation time in this work, we did not observe the entire extrusion
process of the substrate. Hundreds of nanoseconds or more may
be needed for the substrate to overcome the barriers on its way to
the central funnel (Ruggerone et al., 2013; Yao et al., 2013).
The functional rotating mechanism of AcrB assumes that the
conformational transitions of the three monomers occur in a
concerted way, implicating cooperativity in substrate translo-
cation. Kinetic studies of substrate transport of AcrB in intact
cells identified positive cooperativities in the eﬄux of various
cephalosporins (Nagano and Nikaido, 2009) and penicillins (Lim
and Nikaido, 2010). Eﬄux could also be stimulated by differ-
ent kinds of substrates, including solvents (Kinana et al., 2013).
The positive cooperativity in substrate eﬄux could be explained
by the simultaneous binding of substrates to PBPs in the B or
A monomers. Crystal structures of the AcrB-substrate complex
revealed simultaneous substrate binding at DBP of B monomer
and at PBP of A monomer (Nakashima et al., 2011; Eicher
et al., 2012), implying that the substrate in PBP of A monomer
more likely plays a role in stimulating the eﬄux. Simulations
in this study provide the direct evidences that substrate bind-
ing at PBP of A monomer indeed stimulates substrate dissoci-
ation in B monomer through accelerating the conformational
transitions according to the functional rotating mechanism. We
noticed that the conformational changes were overall accelerated
by the substrate in A monomer, not just the local changes in DBP
(Figure 3). This is in line with the observation that the substrate
would not dissociate from the DBP until most of the conforma-
tional changes completed during the functional rotation. There-
fore, the substrate dissociation is allosterically regulated by the
substrate binding in the neighboring monomer. Another possi-
bility we could not rule out, however, is that ligand binding at
PBP of the samemonomer, i.e., in the Bmonomer, may also stim-
ulate the substrate extrusion, although the corresponding inter-
mediate state has not been detected in crystallography studies.
Yet another mechanism of the positive cooperativity in substrate
extrusion proposed by A. Kinana et al. is the direct interference
of the stimulator with the substrate through competitive binding
at the same DBP of B monomer (Kinana et al., 2013). It is worth
noting that in the same study, decreases of Hill coefficients were
observed in the presence of the stimulators (Kinana et al., 2013),
which supports the allosteric mechanism with stimulators bound
at different sites.
Another implication for the observation that substrate bind-
ing at A monomer promotes the protein conformational changes
is that the functional rotation of AcrB trimer is partly ener-
gized by ligand binding in addition to the proton motive force.
The accelerated conformational transition indicates that the free
energy barrier of this process is lowered upon ligand binding.
In other words, substrates are not only passively pumped by the
molecular machine of AcrB, but also actively regulate the func-
tional rotation of AcrB trimer. Recent combined crystallography
and MD simulation study also suggested that drug binding is the
driving force in the A to B (or L to T) transition (Mishra et al.,
2014).
An unexpected observation in this work is that the func-
tional rotation did not squeeze the PBP-bound substrate toward
DBP during the A–B transition, rather it moved away toward
the entrance. This might be attributed to the slight opening
of the PC1–PC2 cleft upon A–B transition (Figure 5), sug-
gesting that substrate translocation from PBP to DBP may
require temporary closure of the cleft. In line with this, par-
tially closed conformations of the cleft have been observed in
monomer A by unbiased substrate-free MD simulations (Fis-
cher and Kandt, 2013). An intermediate state with PC1–PC2
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cleft closed was also identified in another RND transporter ZneA
(Pak et al., 2013). It is most likely that during the functional
rotation, a similar intermediate state between A and B yet iden-
tified also exists in AcrB to prevent the back diffusion of the
substrate.
Although our simulation was conducted on isolated AcrB, the
RND transporter functions together with the periplasmic adaptor
protein AcrA and outer membrane protein TolC as a tripartite
assembly, and AcrA-Mg2+ has been reported to strongly accel-
erate the extrusion of substrate (Zgurskaya and Nikaido, 1999b).
These findings raise an issue of whether the acceleration effect
of multi-substrate binding observed in our simulation would still
work after the association of AcrA-Mg2+. The crystal structure of
heavy-metal eﬄux complex CusBA (Su et al., 2011), a homology
of AcrAB, and the recently reported pseudo-atomic structure of
AcrAB-TolC complex (Du et al., 2014) provide a valuable insight
into the acceleration effect of AcrA-Mg2+. The structures show
that the adaptor protein (CusB or AcrA) forms interactions with
the TolC-docking domain and the subdomains PN2, PC1, and
PC2 of the RND transporter. A noteworthy feature of the inter-
actions between adaptor protein and RND transporter is that the
subdomain PC2 forms much weaker contacts with the adaptor
protein than PN2 and PC1 do. Only two residues on PC2 (Arg705
and Leu714) are located within 4 Å of the adaptor protein and
they form weak van der Waals interactions. The binding of adap-
tor protein may restrain the motions in PN2 and PC1, but is less
likely to disturb the motions of PC2 and the relative motions
between PC1 and PC2. Since the second substrate in monomer A
binds between the PC1 and PC2 subdomains, the adaptor protein
may have little influence on the behavior of the second substrate
and the accelerated conformational changes brought by its bind-
ing. The acceleration effects of AcrA-Mg2+ and multi-substrate
binding may operate simultaneously when AcrB functions. It
is worth noting, however, that the above notions are largely
derived based on the static structures of CusBA and AcrAB-TolC
complexes. Further studies, especially those concerning dynamic
properties, are still required to provide a fuller understanding on
the molecular mechanism of the acceleration effects.
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